1
|
Chaturvedi S and McCrae KR: Diagnosis and
management of the antiphospholipid syndrome. Blood Rev. 31:406–417.
2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
McNeil HP, Chesterman CN and Krilis SA:
Immunology and clinical importance of antiphospholipid antibodies.
Adv Immunol. 49:193–280. 1991. View Article : Google Scholar : PubMed/NCBI
|
3
|
Willis R, Harris EN and Pierangeli SS:
Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost.
38:305–321. 2012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Tanne D, Katzav A, Beilin O, Grigoriadis
NC, Blank M, Pick CG, Landenberg Pv, Shoenfeld Y and Chapman J:
Interaction of inflammation, thrombosis, aspirin and enoxaparin in
CNS experimental antiphospholipid syndrome. Neurobiol Dis.
30:56–64. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
McNeil HP, Simpson RJ, Chesterman CN and
Krilis SA: Anti-phospholipid antibodies are directed against a
complex antigen that includes a lipid-binding inhibitor of
coagulation: Beta 2-glycoprotein I (apolipoprotein H). Proc Natl
Acad Sci USA. 87:4120–4124. 1990. View Article : Google Scholar : PubMed/NCBI
|
6
|
Galli M, Comfurius P, Maassen C, Hemker
HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF and
Bevers EM: Anticardiolipin antibodies (ACA) directed not to
cardiolipin but to a plasma protein cofactor. Lancet.
335:1544–1547. 1990. View Article : Google Scholar : PubMed/NCBI
|
7
|
de Laat B, Derksen RH, Urbanus RT and de
Groot PG: IgG antibodies that recognize epitope Gly40-Arg43 in
domain I of beta 2-glycoprotein I cause LAC, and their presence
correlates strongly with thrombosis. Blood. 105:1540–1545. 2005.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Forastiero RR, Martinuzzo ME and de
Larrañaga GF: Circulating levels of tissue factor and
proinflammatory cytokines in patients with primary antiphospholipid
syndrome or leprosy related antiphospholipid antibodies. Lupus.
14:129–136. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Clemens N, Frauenknecht K, Katzav A,
Sommer C and von Landenberg P: In vitro effects of antiphospholipid
syndrome-IgG fractions and human monoclonal antiphospholipid IgG
antibody on human umbilical vein endothelial cells and monocytes.
Ann NY Acad Sci. 1173:805–813. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Levi M and van der Poll T: Two-way
interactions between inflammation and coagulation. Trends
Cardiovasc Med. 15:254–259. 2005. View Article : Google Scholar : PubMed/NCBI
|
11
|
ten Cate JW, van der Poll T, Levi M, ten
Cate H and van Deventer SJ: Cytokines: Triggers of clinical
thrombotic disease. Thromb Haemost. 78:415–419. 1997. View Article : Google Scholar : PubMed/NCBI
|
12
|
Meroni PL, Raschi E, Testoni C, Tincani A,
Balestrieri G, Molteni R, Khamashta MA, Tremoli E and Camera M:
Statins prevent endothelial cell activation induced by
antiphospholipid (anti-beta2-glycoprotein I) antibodies: Effect on
the proadhesive and proinflammatory phenotype. Arthritis Rheum.
44:2870–2878. 2001. View Article : Google Scholar : PubMed/NCBI
|
13
|
Pierangeli SS, Colden-Stanfield M, Liu X,
Barker JH, Anderson GL and Harris EN: Antiphospholipid antibodies
from antiphospholipid syndrome patients activate endothelial cells
in vitro and in vivo. Circulation. 99:1997–2002. 1999. View Article : Google Scholar : PubMed/NCBI
|
14
|
Zhou H, Sheng L, Wang H, Xie H, Mu Y, Wang
T and Yan J: Anti-β2GPI/β2GPI stimulates activation of THP-1 cells
through TLR4/MD-2/MyD88 and NF-κB signaling pathways. Thromb Res.
132:742–749. 2013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Vega-Ostertag ME, Ferrara DE,
Romay-Penabad Z, Liu X, Taylor WR, Colden-Stanfield M and
Pierangeli SS: Role of p38 mitogen-activated protein kinase in
antiphospholipid antibody-mediated thrombosis and endothelial cell
activation. J Thromb Haemost. 5:1828–1834. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Medzhitov R, Preston-Hurlburt P and
Janeway CA Jr: A human homologue of the Drosophila Toll protein
signals activation of adaptive immunity. Nature. 388:394–397. 1997.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Medzhitov R and Janeway CA Jr: Innate
immunity: The virtues of a nonclonal system of recognition. Cell.
91:295–298. 1997. View Article : Google Scholar : PubMed/NCBI
|
18
|
Werling D and Jungi TW: TOLL-like
receptors linking innate and adaptive immune response. Vet Immunol
Immunopathol. 91:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
|
19
|
Xia L, Zhou H, Hu L, Xie H, Wang T, Xu Y,
Liu J, Zhang X and Yan J: Both NF-κB and c-Jun/AP-1 involved in
anti-β2GPI/β2GPI-induced tissue factor expression in monocytes.
Thromb Haemost. 109:643–651. 2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhou H, Chen D, Xie H, Xia L, Wang T, Yuan
W and Yan J: Activation of MAPKs in the anti-β2GPI/β2GPI-induced
tissue factor expression through TLR4/IRAKs pathway in THP-1 cells.
Thromb Res. 130:e229–e235. 2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Xie HX, Zhou H, Wang HB, Chen DD, Wang T,
Zhang XM, Xia LF and Mu Y: The activation of TRIF-dependent
signaling pathway in THP-1 cells induced by β2
GPI/anti-β2 GPI antibodies complex. Xi Bao Yu Fen Zi
Mian Yi Xue Za Zhi. 27:1280–1283, 1287. 2011.(In Chinese).
PubMed/NCBI
|
22
|
Ethics and Animal Use, . Guide for the
Care and Use of Laboratory Animals. 8th. National Academies Press
(US); Washington (DC): 2011, PubMed/NCBI
|
23
|
Xie H, Kong X, Zhou H, Xie Y, Sheng L,
Wang T, Xia L and Yan J: TLR4 is involved in the pathogenic effects
observed in a murine model of antiphospholipid syndrome. Clin
Immunol. 160:198–210. 2015. View Article : Google Scholar : PubMed/NCBI
|
24
|
He C, Zhang G, Zhou H, Cheng S and Farwa
A: Effects of Toll-like receptor 4 on β2-glycoprotein I-induced
splenic T cell subsets differentiation. Immunol Lett. 198:17–25.
2018. View Article : Google Scholar : PubMed/NCBI
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Brandt KJ, Kruithof EK and de Moerloose P:
Receptors involved in cell activation by antiphospholipid
antibodies. Thromb Res. 132:408–413. 2013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Pierangeli SS, Vega-Ostertag ME, Raschi E,
Liu X, Romay-Penabad Z, De Micheli V, Galli M, Moia M, Tincani A,
Borghi MO, et al: Toll-like receptor and antiphospholipid mediated
thrombosis: In vivo studies. Ann Rheum Dis. 66:1327–1333. 2007.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Gao MY, Chen L, Yang L, Yu X, Kou JP and
Yu BY: Berberine inhibits LPS-induced TF procoagulant activity and
expression through NF-κB/p65, Akt and MAPK pathway in THP-1 cells.
Pharmacol Rep. 66:480–484. 2014. View Article : Google Scholar : PubMed/NCBI
|
29
|
Li X, Zheng Z, Li X and Ma X:
Unfractionated heparin inhibits lipopolysaccharide-induced
inflammatory response through blocking p38 MAPK and NF-κB
activation on endothelial cell. Cytokine. 60:114–121. 2012.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Willis R and Pierangeli SS:
Anti-β2-glycoprotein I antibodies. Ann NY Acad Sci. 1285:44–58.
2013. View Article : Google Scholar : PubMed/NCBI
|
31
|
Zhou H, Wolberg AS and Roubey RA:
Characterization of monocyte tissue factor activity induced by IgG
antiphospholipid antibodies and inhibition by dilazep. Blood.
104:2353–2358. 2004. View Article : Google Scholar : PubMed/NCBI
|
32
|
Zhou H, Wang H, Li N, Yu Y, Huang H, Yan Y
and Wang T: Annexin A2 mediates anti-beta 2 GPI/beta 2 GPI-induced
tissue factor expression on monocytes. Int J Mol Med. 24:557–562.
2009. View Article : Google Scholar : PubMed/NCBI
|
33
|
Zhou H, Ling S, Yu Y, Wang T and Hu H:
Involvement of Annexin A2 in anti-beta2GPI/beta2GPI-induced tissue
factor expression on monocytes. Cell Res. 17:737–739. 2007.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Zhou H, Yan Y, Xu G, Zhou B, Wen H, Guo D,
Zhou F and Wang H: Toll-like receptor (TLR)-4 mediates
anti-β2GPI/β2GPI-induced tissue factor expression in THP-1 cells.
Clin Exp Immunol. 163:189–198. 2011. View Article : Google Scholar : PubMed/NCBI
|
35
|
Xie H, Zhou H, Wang H, Chen D, Xia L, Wang
T and Yan J: Anti-β(2)GPI/β(2)GPI induced TF and TNF-α expression
in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling
pathways. Mol Immunol. 53:246–254. 2013. View Article : Google Scholar : PubMed/NCBI
|
36
|
Hurst J, Lorenz M, Prinz N and von
Landenberg P: The roll of Toll-like receptors in the
antiphospholipid syndrome. Curr Rheumatol Rep. 12:58–63. 2010.
View Article : Google Scholar : PubMed/NCBI
|
37
|
Zelaya H, Rothmeier AS and Ruf W: Tissue
factor at the crossroad of coagulation and cell signaling. J Thromb
Haemost. 16:1941–1952. 2018. View Article : Google Scholar : PubMed/NCBI
|
38
|
Pierangeli SS, Espinola RG, Liu X and
Harris EN: Thrombogenic effects of antiphospholipid antibodies are
mediated by intercellular cell adhesion molecule-1, vascular cell
adhesion molecule-1, and P-selectin. Circ Res. 88:245–250. 2001.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Ghosh TK, Mickelson DJ, Solberg JC, Lipson
KE, Inglefield JR and Alkan SS: TLR-TLR cross talk in human PBMC
resulting in synergistic and antagonistic regulation of type-1 and
2 interferons, IL-12 and TNF-alpha. Int Immunopharmacol.
7:1111–1121. 2007. View Article : Google Scholar : PubMed/NCBI
|
40
|
Benhamou Y, Bellien J, Armengol G,
Brakenhielm E, Adriouch S, Iacob M, Remy-Jouet I, Le Cam-Duchez V,
Monteil C, Renet S, et al: Role of Toll-like receptors 2 and 4 in
mediating endothelial dysfunction and arterial remodeling in
primary arterial antiphospholipid syndrome. Arthritis Rheumatol.
66:3210–3220. 2014. View Article : Google Scholar : PubMed/NCBI
|
41
|
Yu Y, Zhou H, Xia L, Kong X, Xie Y, Xie H,
He C and Cheng S: TLR2 blockade reduces TNF-α expression induced by
β2GP1/anti-β2GP1 complex in mouse peritoneal macrophages. Xi Bao Yu
Fen Zi Mian Yi Xue Za Zhi. 32:446–450, 456. 2016.(In Chinese).
PubMed/NCBI
|
42
|
Sikara MP, Routsias JG, Samiotaki M,
Panayotou G, Moutsopoulos HM and Vlachoyiannopoulos PG: {beta}2
Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4):
Implications for the pathogenesis of antiphospholipid syndrome.
Blood. 115:713–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
43
|
Kawai T and Akira S: Signaling to
NF-kappaB by Toll-like receptors. Trends Mol Med. 13:460–469. 2007.
View Article : Google Scholar : PubMed/NCBI
|
44
|
Olson CM, Hedrick MN, Izadi H, Bates TC,
Olivera ER and Anguita J: p38 mitogen-activated protein kinase
controls NF-kappaB transcriptional activation and tumor necrosis
factor alpha production through RelA phosphorylation mediated by
mitogen- and stress-activated protein kinase 1 in response to
Borrelia burgdorferi antigens. Infect Immun. 75:270–277. 2007.
View Article : Google Scholar : PubMed/NCBI
|
45
|
Guo RM, Xu WM, Lin JC, Mo LQ, Hua XX, Chen
PX, Wu K, Zheng DD and Feng JQ: Activation of the p38 MAPK/NF-κB
pathway contributes to doxorubicin-induced inflammation and
cytotoxicity in H9c2 cardiac cells. Mol Med Rep. 8:603–608. 2013.
View Article : Google Scholar : PubMed/NCBI
|
46
|
Ruiz-Irastorza G and Khamashta MA: Lupus
and pregnancy: Integrating clues from the bench and bedside. Eur J
Clin Invest. 41:672–678. 2011. View Article : Google Scholar : PubMed/NCBI
|
47
|
Matsunaga N, Tsuchimori N, Matsumoto T and
Ii M: TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like
receptor (TLR) 4 signaling, binds selectively to TLR4 and
interferes with interactions between TLR4 and its adaptor
molecules. Mol Pharmacol. 79:34–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
48
|
Li J, Csakai A, Jin J, Zhang F and Yin H:
Therapeutic developments targeting Toll-like receptor-4-mediated
neuroinflammation. ChemMedChem. 11:154–165. 2016. View Article : Google Scholar : PubMed/NCBI
|
49
|
Comarmond C and Cacoub P: Antiphospholipid
syndrome: From pathogenesis to novel immunomodulatory therapies.
Autoimmun Rev. 12:752–757. 2013. View Article : Google Scholar : PubMed/NCBI
|